We are in a transformative era for the pharmaceutical industry, with steady growth of revolutionary large molecule products aimed at addressing previously unmet medical needs. We must adopt new strategies and business models to help drive these discoveries from concept to reality. Drug manufacturers need sustainable partnerships throughout the product life cycle, rather than the historically transactional relationships. Read more in this e-book.
To ensure that a commercial biomanufacturing process is in a state of control, life sciences companies must create and successfully execute initiatives to meet continued process verification (CPV) and other monitoring guidelines. Learn how to navigate the major steps of implementing a global monitoring plan for continued process verification.
A model of human IBD has been established to enable the screening and detailed characterization of novel therapeutic agents combining measures that bridge noninvasive and high-throughput testing with clinically relevant endpoints of this disease.